According to the modified Matrigel-Boyden chamber assay, cellular invasiveness of the non-metastatic RCC cell lines (Caki-2 and A498) was significantly decreased in EphA2 siRNA-treated cells after 48-hours of transfection compared to cells treated with control siRNA and the untreated control (Fig 5). This evidence concerns the gene EPHA2 and renal cell carcinoma.